December 1, 2003Endocrine Related CancerOpen Access

Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions.

View Full Paper

Ask AI

Bookmark

Structured PICO

Population

Patients at risk for common cancers (breast, prostate, lung, colon) and preclinical models of human cancers

Intervention

Interventions which antagonize IGF-IR signaling or augment IGFBP-3 function

Outcome

Cancer risk and tumor cell growth

Deregulation of the IGF axis is implicated in cancer development, making it a potential target for novel antineoplastic strategies.

No takes yet. Share an insight, caveat, or question.

Supports IGF axis targeting in oncology; leaves open clinical translation from Level 5 evidence.

Jerome et al. (2003) studied this question.

View Full Paper

Ask AI

Bookmark